| Name | Saroglitazar Magnesium |
| Description | Saroglitazar Magnesium is a novel peroxissome proliferator-activated receptor (PPAR) agonist with significant activation activity against PPARα (EC50 0.65pM) and moderate activation against PPARγ (EC50 3 nM). |
| In vivo | In db/db mice, Saroglitazar (0.01-3 mg/kg per day, orally) treatment with 12-day causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose.in Wistar rats and marmosets A 90-day repeated dose comparative study confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (4.44 mM), Sonication is recommended.
DMSO : 112.5 mg/mL (124.8 mM), Sonication is recommended.
|
| Keywords | Saroglitazar Magnesium | PPARγ | PPARα |
| Inhibitors Related | PHYTOL | Rosiglitazone | Retinoic acid | Daidzein | Fenofibrate | Magnesium acetate tetrahydrate | Maltitol | Naringenin | 2,3-Butanediol | NPC 15199 | Icariin | Cloxiquine |
| Related Compound Libraries | Nuclear Receptor Compound Library | Ferroptosis Compound Library | Bioactive Compound Library | Anti-Diabetic Compound Library | Anti-Obesity Compound Library | Multi-Target Compound Library | Drug Repurposing Compound Library | Mitochondria-Targeted Compound Library | Lipid Metabolism Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Transcription Factor-Targeted Compound Library |
United States
